Patents by Inventor Judith A. Varner
Judith A. Varner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11679100Abstract: The present invention is based on the finding that CD11b signaling inhibits immune suppression, modulates neovascularization and promotes anti-tumor immune responses in models of murine and human cancer. As such, provided herein are methods of treating cancer using an antibody, protein or small molecule that modulates CD11b activity or expression. Also provided are methods of identifying cancer that is amenable to such treatment and/or increasing susceptibility of cancer cells to treatment with a chemotherapeutic agent.Type: GrantFiled: May 30, 2019Date of Patent: June 20, 2023Assignee: The Regents of the University of CaliforniaInventors: Judith Varner, Michael C. Schmid
-
Patent number: 11344559Abstract: The present disclosure relates to PI3K? inhibitors and methods of their use.Type: GrantFiled: June 25, 2020Date of Patent: May 31, 2022Assignee: The Regents of the University of CaliforniaInventors: Judith Varner, Rommie Amaro, Megan Kaneda, Robert Malmstrom, Victoria Feher
-
Publication number: 20210212997Abstract: The present invention is based on the finding that CD11b signaling inhibits immune suppression, modulates neovascularization and promotes anti-tumor immune responses in models of murine and human cancer. As such, provided herein are methods of treating cancer using an antibody, protein or small molecule that modulates CD11b activity or expression. Also provided are methods of identifying cancer that is amenable to such treatment and/or increasing susceptibility of cancer cells to treatment with a chemotherapeutic agent.Type: ApplicationFiled: May 30, 2019Publication date: July 15, 2021Applicant: The Regents of the University of CaliforniaInventors: Judith Varner, Michael C. Schmid
-
Publication number: 20200405730Abstract: The present disclosure relates to PI3K? inhibitors and methods of their use.Type: ApplicationFiled: June 25, 2020Publication date: December 31, 2020Inventors: Judith Varner, Rommie Amaro, Megan Kaneda, Robert Malmstrom, Victoria Feher
-
Patent number: 9403908Abstract: The present invention satisfies the need in the art by providing methods for altering hematopoietic progenitor cell adhesion and/or migration to a target tissue, and for altering hematopoietic progenitor cell differentiation into a second cell type. The invention also provides methods for screening test compounds for altering the level of hematopoietic progenitor cell adhesion and/or migration to a target tissue, and for altering hematopoietic progenitor cell differentiation into a second cell type. The invention further provides methods for isolating hematopoietic progenitor cells.Type: GrantFiled: September 28, 2004Date of Patent: August 2, 2016Assignee: The Regents of the University of CaliforniaInventor: Judith A. Varner
-
Patent number: 8808698Abstract: The present invention is directed to compositions and methods for inhibiting the development of new lymphatic vessels, and for inhibiting tumor cell dissemination through the lymphatics. In preferred embodiments, the present invention utilizes agents that inhibit the specific binding of integrin alpha4beta1 (?4?1, VLA-4) to one or more of its ligands. The invention further relates to methods for screening test compounds for their ability to inhibit undesirable lymphangiogenesis and/or tumor metastasis.Type: GrantFiled: February 5, 2007Date of Patent: August 19, 2014Assignee: The Regents of the University of CaliforniaInventors: Judith Varner, Barbara Garmy-Susini
-
Patent number: 8454958Abstract: The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting ?5?1 integrin in the tissue with an agent that interferes with specific binding of the ?5?1 integrin to a ligand expressed in the tissue. The invention further provides methods of reducing or inhibiting angiogenesis in a tissue in an individual, by administering to the individual an agent that interferes with the specific binding of ?5?1 integrin to a ligand expressed in the tissue; and methods of reducing the severity of a pathological condition associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding of ?5?1 integrin to a ligand in a tissue associated with the pathological condition.Type: GrantFiled: December 7, 2011Date of Patent: June 4, 2013Assignee: The Regents of the University of CaliforniaInventor: Judith A. Varner
-
Publication number: 20120128696Abstract: The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting ?5?1 integrin in the tissue with an agent that interferes with specific binding of the ?5?1 integrin to a ligand expressed in the tissue. The invention further provides methods of reducing or inhibiting angiogenesis in a tissue in an individual, by administering to the individual an agent that interferes with the specific binding of ?5?1 integrin to a ligand expressed in the tissue; and methods of reducing the severity of a pathological condition associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding of ?5?1 integrin to a ligand in a tissue associated with the pathological condition.Type: ApplicationFiled: December 7, 2011Publication date: May 24, 2012Applicant: The Regents of the University of CaliforniaInventor: Judith A. VARNER
-
Publication number: 20110177528Abstract: The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting ?5?1 integrin in the tissue with an agent that interferes with specific binding of the ?5?1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds ?5?1 integrin, and detecting specific binding of the agent to ?5?1 integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual.Type: ApplicationFiled: February 24, 2011Publication date: July 21, 2011Applicant: The Regents of the University of CaliforniaInventor: Judith A. VARNER
-
Publication number: 20100278837Abstract: This invention relates to the discovery of the convergence of diverse receptors and signaling pathways on the PI3gamma dependent activation of VLA4 (integrin a4b1). In particular, the invention relates to the role of myeloid cells in tumor inflammation and metastasis. The invention provides methods for inhibiting cancer in a subject comprising administering to a subject having cancer that comprises endothelial cells a therapeutically effective amount of a PI-3-kinase gamma inhibitor that reduces at least one of (a) adhesion of myeloid cells to the endothelial cells, (b) migration of myeloid cells into the cancer, (c) growth of the cancer, (d) activation of integrin a4b1 that is comprised on the myeloid cells, and (e) clustering of integrin a4b1 that is comprised on the myeloid cells.Type: ApplicationFiled: March 9, 2010Publication date: November 4, 2010Inventors: Judith A. Varner, David A. Cheresh, Michael C. Schmid
-
Patent number: 7824680Abstract: The invention provides methods for detecting and inhibiting angiogenesis, endothelial cell adhesion, and endothelial cell migration using agents which inhibit the specific binding of integrin ?4?1 to one or more of its ligands. The invention further provides methods for screening test compounds for their ability to inhibit angiogenesis, endothelial cell adhesion, or endothelial cell migration by employing agents which inhibit the specific binding of integrin ?4?1 to one or more of its ligands. The invention additionally relates to methods for isolating endothelial progenitor cells which express integrin ?4?1. The methods of the invention are useful in, for example, diagnosing and inhibiting pathological conditions that are associated with angiogenesis, endothelial cell adhesion, and/or endothelial cell migration.Type: GrantFiled: August 1, 2002Date of Patent: November 2, 2010Assignee: The Regents of the University of CaliforniaInventor: Judith A. Varner
-
Publication number: 20100255502Abstract: The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting ?5?1 integrin in the tissue with an agent that interferes with specific binding of the ?5?1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds ?5?1 integrin, and detecting specific binding of the agent to ?5?1 integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual.Type: ApplicationFiled: October 15, 2009Publication date: October 7, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: JUDITH A. VARNER
-
Publication number: 20100055089Abstract: The present invention is directed to compositions and methods for inhibiting the development of new lymphatic vessels, and for inhibiting tumor cell dissemination through the lymphatics. In preferred embodiments, the present invention utilizes agents that inhibit the specific binding of integrin alpha4beta1 (?4?1, VLA-4) to one or more of its ligands. The invention further relates to methods for screening test compounds for their ability to inhibit undesirable lymphangiogenesis and/or tumor metastasis.Type: ApplicationFiled: February 5, 2007Publication date: March 4, 2010Inventors: Judith Varner, Barbara Garmy-Susini
-
Publication number: 20090130124Abstract: The present invention satisfies the need in the art by providing methods for altering hematopoietic progenitor cell adhesion and/or migration to a target tissue, and for altering hematopoietic progenitor cell differentiation into a second cell type. The invention also provides methods for screening test compounds for altering the level of hematopoietic progenitor cell adhesion and/or migration to a target tissue, and for altering hematopoietic progenitor cell differentiation into a second cell type. The invention further provides methods for isolating hematopoietic progenitor cells.Type: ApplicationFiled: September 28, 2004Publication date: May 21, 2009Inventor: Judith A. Varner
-
Publication number: 20080233108Abstract: The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting ?5?1 integrin in the tissue with an agent that interferes with specific binding of the ?5?1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds ?5?1 integrin, and detecting specific binding of the agent to ?5?1 integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual.Type: ApplicationFiled: August 20, 2007Publication date: September 25, 2008Applicant: The Regents of the University of CaliforniaInventor: Judith A. Varner
-
Publication number: 20080188641Abstract: The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting ?5?1 integrin in the tissue with an agent that interferes with specific binding of the ?5?1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds ?5?1 integrin, and detecting specific binding of the agent to ?5?1 integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual.Type: ApplicationFiled: May 1, 2007Publication date: August 7, 2008Applicant: University of California San DiegoInventor: Judith A. Varner
-
Publication number: 20080113898Abstract: The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting ?5?1 integrin in the tissue with an agent that interferes with specific binding of the ?5?1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds ?5?1 integrin, and detecting specific binding of the agent to ?5?1 integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual.Type: ApplicationFiled: August 21, 2007Publication date: May 15, 2008Applicant: The Regents of the University of CaliforniaInventor: Judith A. Varner
-
Patent number: 7311911Abstract: The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting ?5?1 integrin in the tissue with an agent that interferes with the specific binding of ?5?1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds ?5?1 integrin, and detecting specific binding of the agent to ?5?1 integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual; methods of reducing or inhibiting angio genesis in a tissue in an individual; and methods of reducing the severity of a pathological condition associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding of ?5?1 integrin to a ligand in a tissue associated with the pathological condition.Type: GrantFiled: October 14, 2003Date of Patent: December 25, 2007Assignee: The Regents of the University of CaliforniaInventor: Judith A. Varner
-
Publication number: 20060241067Abstract: The invention relates to methods for detecting and inhibiting angiogenesis, cell migration, cell adhesion, and/or cell survival in endothelial and non-endothelial cells as well as in normal and tumor cells. The invention further relates to methods for screening test compounds for their ability to inhibit angiogenesis, cell migration, cell adhesion, and/or cell survival.Type: ApplicationFiled: June 25, 2003Publication date: October 26, 2006Inventors: Judith Varner, Manjiri Bakre, Hui Jin
-
Patent number: 7056506Abstract: The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting ?5?1 integrin in the tissue with an agent that interferes with specific binding of the ?5?1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds ?5?1 integrin, and detecting specific binding of the agent to ?5?1 integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual.Type: GrantFiled: July 5, 2002Date of Patent: June 6, 2006Assignee: The Regents of the University of CaliforniaInventor: Judith A. Varner